Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 37 - Drugs for immunological or allergic disorders
Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141)
10/2008
10/30/2008WO2008128997A1 Aminoalkyl glucosamine phosphate compounds for treating autoimmune diseases
10/30/2008WO2008128951A1 Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (s1p) agonists
10/30/2008WO2008128538A1 Src family kinase inhibitors
10/30/2008WO2008128456A1 The functional epitope of osteopontin, the anti-osteoponin monoclonal antibody and use thereof
10/30/2008WO2008100635A8 1- [3- (monocyclic amino) propyl] - 4, 5, 6, 7-tetrahydro-1h-pyrazolo [4, 3-c] -pyridines as modulators of cathepsin s
10/30/2008WO2008100498A3 Treatment of inflammatory diseases using placental stem cells
10/30/2008WO2008074752A3 Indolylmaleimide derivatives as kinase inhibitors
10/30/2008WO2008064320A3 Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity
10/30/2008WO2008063898A3 Methods of treating idiopathic thrombocytopenia purpura using a gm-csf antagonist
10/30/2008US20080269875 Coating for a Medical Device Having an Anti-Thrombotic Conjugate
10/30/2008US20080269465 Tumor necrosis factor specific immunoglobulin for use in prevention and treatment of rheumatoid arthritis, ulcerative colitis, multiple sclerosis and crohn's disease
10/30/2008US20080269349 administering an isolated astaxanthin and a mono- or di-ester thereof; controlling cytokine or TGF- alpha -related gene expression; reducing muscle atrophy, treating diabetes
10/30/2008US20080269347 injectable pharmaceutical composition also including EDTA, antioxidant, selected from cysteine, citric acid, thioglycerol, acetylcysteine; treating anaphylaxis, asthma, or cardiac arrest; stable in light, oxygen, and/or heat conditions without a stabilizer
10/30/2008US20080269335 Crth2 Receptor Antagonists
10/30/2008US20080269317 Compounds for Covalent Binding to MD-2 and Effect on the Immune Response
10/30/2008US20080269304 Parakeratosis inhibitor, pore-shrinking agent and skin preparation for external use
10/30/2008US20080269303 Diaryloxazole carboxamide derivatives for treating a disease selected from appetite disorder, metabolic disorder, gastrointestinal disorder, inflammatory phenomena, immune system disease, psychotic disorder, alcohol dependency and nicotine dependency
10/30/2008US20080269282 Including semicarbazide-sensitive amine oxidase (vascular adhesion protein-1, VAP-I), and therapeutic use in inflammatory diseases, diabetes and its associated complications, atherosclerosis, neurodegenerative diseases, obesity, hypertension and cancer; N1-hydroxy-N2-[(4-bromophenyl)carbonyl]glycinamide
10/30/2008US20080269280 Antiinflammatory agents; rheumatic diseases; multiple sclerosis
10/30/2008US20080269273 Administering loratadine and montelukast; cardiovascular disorders; antiallergens; antiinflammatory agents
10/30/2008US20080269260 Using a purine compound; antiallergens; antiinflammatory agents; cognition activators; drug abuse; schizophenia; Alzheimer's disease; Parkinson's disease
10/30/2008US20080269241 Bicyclic aminopropyl tetrahydro-pyrazolo-pyridine modulators of cathepsin s
10/30/2008US20080269239 Antiinflammatory agents; asthma;antiarthritic agents; psoriasis; inflammatory bowel disorders; rhinitis; dermatitis; antiallergens
10/30/2008US20080269235 e.g. 5-Acetyl-4-[(3,5-difluorophenyl)amino]-2-ethyl-6-phenylpyridazin-3(2H)-one; Tumor Necrosis Factor alpha antagonist; antiinflammatory agent, autoimmune diseases; chronic obstructive pulmonary disease, rheumatoid arthritis, psoriasis, ulcerative colitis, and Crohn's disease
10/30/2008US20080269231 Phenazine Compounds and Use Thereof in Autoimmune and Inflammatory Disease
10/30/2008US20080269227 Autoimmune diseases; antiinflamamtory agents, cardiovascular disorders; neurodegenerative diseases, kidney diseases, anticancer agents; platelet aggregation
10/30/2008US20080269207 Anticancer agents; such as 4-acetylamino-1H-pyrazole-3-carboxylic acid (4-fluoro-phenyl)-amide
10/30/2008US20080269200 Antiinflammatory agents; tissue repair; rheumatic disorders; asthma; chronic onstructive pulmonary disease; osteoporosis; psoriasis; Alzheimer's disease; transplant rejection; stroke; antidiabetic agents; glomerulonephritis; anticancer agents
10/30/2008US20080269189 Method for Avoiding Edema in the Treatment or Prevention of Ppary-Responsive Diseases, Including Cancer
10/30/2008US20080269170 Novel 2,4-Dianilinopyrimidine Derivatives, the Preparation Thereof, Their Use as Medicaments, Pharmaceutical Compositions and, in Particular, as IKK Inhibitors
10/30/2008US20080269160 Immune response against antigen in vivo; gold particle bombardment, nucleotide sequence encoding chimeric protein, antigen in one nucleic acid in an adenoviral vector; chimeric protein is myristoylation membrane targeting region; AP1903 ligand-binding region; CD40 cytoplasmic polypeptide region
10/30/2008US20080269147 Used in targeting specific mRNAs for degradation in mammalian cells where use of long dsRNAs to elicit RNAi is usually not practical, presumably because of the deleterious effects of the interferon response; autoimmune disease; tumor-associated gene
10/30/2008US20080269137 Compositions and methods for modulating the immune system
10/30/2008US20080269128 Albumin Fusion Proteins
10/30/2008US20080269127 Albumin Fusion Proteins
10/30/2008US20080269126 Albumin Fusion Proteins
10/30/2008US20080269125 Albumin Fusion Proteins
10/30/2008US20080268536 Humanized Anti-CCR2 Antibodies and Methods of Use Therefor
10/30/2008US20080268077 Process for Strengthening the Barrier Function of Undamaged Skin
10/30/2008US20080268073 derived from at least one plant selected from the group consisting of plants belonging to Ginkgoaceae, plants belonging to Cucurbitaceae, Rutaceae, Laminariaceae, Myrtaceae and Compositae, and a medicament, a quasi-drug, cosmetics and a food, each comprising the inhibitor
10/30/2008US20080268045 Sustained release methotrexate formulations and methods of use thereof
10/30/2008US20080268027 Oral administering a drug; drying self-supporting polymer film and drug dosage
10/30/2008US20080268013 Polyethylene Oxide Polymers Including Anti-Inflammatory Glycodendrons
10/30/2008US20080267998 Combinations of gene deletions for live attenuated shigella vaccine strains
10/30/2008US20080267997 Modified Viral Particles with Immunogenic Properties and Reduced Lipid Content Useful for Treating and Preventing Infectious Diseases
10/30/2008US20080267994 in vitro culturing; producing immunostimulants for a specific immune response and individuals who suffer from HIV infection, certain cancers, allergies, have received transplants; Acute Myeloid Leukemia cancers treatments, and autoimmune diseases such as Systemic Lupus Erythematosus; anti-viral cytokines
10/30/2008US20080267992 Sars Virus Vaccine with Adenovirus Carrier and Preparation Method Thereof, and Use of Sars Virus S Gene for Preparation of Vaccine
10/30/2008US20080267989 Self aggregating monomeric fusion protein for use in induction of immune response to human immunodeficiency viral infection
10/30/2008US20080267987 Major histocompatibility complex polypeptide for use in targeting, detecting and purifying antigen-specific T-cells; for treatment and prevention of inflammatory, arthritic and autoimmune disease
10/30/2008US20080267984 Using low density lipoprotein receptor specific immunoglobulin to increase receptor expression on antigen presenting cells; immunotherapy; treating infection, autoimmune, graft vs host and allergic disorders
10/30/2008US20080267982 Generating E7 oncoprotein specific immunoglobulin for use as evaluative tool in diagnosing urogenital cell proliferative, brain and prion disorders
10/30/2008US20080267974 Tumor necrosis factor specific immunoglobulin for use in diagnosis and treatment of autoimmune diseases
10/30/2008US20080267967 Modulation of cd200 receptors
10/30/2008US20080267966 Polypeptides from Non-Typeable Haemophilus Influenzae
10/30/2008US20080267965 Use of Bcma as an Immunoregulatory Agent
10/30/2008US20080267962 Albumin Fusion Proteins
10/30/2008US20080267866 Cross-bridged tetraamine macrocycles complexed with transition metal ions, radioactive metal species, fluorescent tag; as CXCR4 co-receptor antagonist is a dosage form for treatment of HIV; radiopharmaceutical for imaging chemokine receptors; drug screening assays for chemokine receptor binding
10/30/2008CA2688670A1 Src family kinase inhibitors
10/30/2008CA2686393A1 Composition comprising lactic acid bacterium having high anti-allergic activity, and method for production of the lactic acid bacterium
10/30/2008CA2685185A1 The functional epitope of osteopontin, the anti-osteoponin monoclonal antibody and use thereof
10/30/2008CA2684555A1 Use of hemagglutinin of the african swine fever virus as an adjuvant
10/30/2008CA2684453A1 Medicaments and methods to treat autoimmune disease and cancer
10/30/2008CA2684385A1 Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (s1p) agonists
10/30/2008CA2684003A1 Novel compounds as cannabinoid receptor ligands
10/30/2008CA2682605A1 Single chain fc, methods of making and methods of treatment
10/30/2008CA2680769A1 Nitrogenated fused ring derivative, pharmaceutical composition comprising the same, and use of the same for medical purposes
10/30/2008CA2678004A1 Utilisation de lactobacillus casei pour renforcer la protection induite par la vaccination anti-grippale
10/30/2008CA2667637A1 Fusion proteins comprising an anti-inflammatory cytokine and an antigen for treatment of immune disorders
10/29/2008EP1985706A2 Di- or oligomer of a dimer, trimer, quatromer or pentamer of recombinant fusion proteins
10/29/2008EP1985635A1 Process for producing polysaccharide from coffee bean or/and coffee extraction residue
10/29/2008EP1985634A1 Modulators of p-selectin glycoprotein ligand 1
10/29/2008EP1985632A2 Use of VEGF2 antibodies for inhibiting photoreceptor cell proliferation
10/29/2008EP1985306A2 TRX1 antibody and uses therefor
10/29/2008EP1985301A1 Method of inducing cytotoxic t-cell, cytotoxic t-cell inducer and, produced therewith, pharmaceutical composition and vaccine
10/29/2008EP1984006A1 Conditioned blood composition and method for its production
10/29/2008EP1983990A1 A3 adenosine receptor allosteric modulators
10/29/2008EP1983987A2 Dihydrodiazepines useful as inhibitors of protein kinases
10/29/2008EP1983976A2 Composition comprising a polyunsaturated fatty acid for improving membrane composition
10/29/2008EP1737958B1 Compositions and methods for inducing anti-tumor immunity
10/29/2008EP1653914A4 Oxime substituted imidazo-containing compounds
10/29/2008EP1641758B1 Diphenylpyridine derivatives, preparation and therapeutic application thereof
10/29/2008EP1556055B1 Cyclic nucleotide phosphodiesterase inhibitors having a benzodiazepine structure and their use in therapy
10/29/2008EP1406650B1 Use of poly-glu, tyr for neuroprotection therapy of the cns or pns
10/29/2008EP1255560B1 Cd40 ligand adjuvant for respiratory syncytial virus vaccine
10/29/2008EP1137434B1 New cancer treatments
10/29/2008EP1076564B1 Compositions for enhancing antigen-presenting cells and anti-tumor responses in a human patient
10/29/2008EP1054693B1 Inhibitors of complement activation
10/29/2008EP0990440B1 Pharmaceutical composition comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol, a lecithin and a saccharide
10/29/2008EP0961831B1 Human endokine alpha
10/29/2008CN101296944A Engineered anti-IL-23 antibodies
10/29/2008CN101294128A Truffle soaked wine
10/29/2008CN101294127A Hippophae rhamnoides health wine
10/29/2008CN101293931A Anti-shrimp white spot syndrome virus recombined bacterium typhosum strain, preparation and uses thereof
10/29/2008CN101293916A Monoclone antibody with combined function epiposition, specificity of osteopontin and uses thereof
10/29/2008CN101293894A 2-propylidene-19-nor-vitamin D compounds
10/29/2008CN101293889A Water-soluble arteannuin derivative and preparation method thereof
10/29/2008CN101293867A Phenylalanine enamide derivatives possessing a cyclobutene group, for use as integrin inhibitors
10/29/2008CN101293097A Recombined staphylococcus aureus enterotoxin O oral preparation and application thereof
10/29/2008CN101293096A Recombined staphylococcus aureus enterotoxin N oral preparation and application thereof
10/29/2008CN101293095A Recombined staphylococcus aureus enterotoxin Q oral preparation and application thereof
1 ... 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 ... 1172